The company showed positive developments in revenue growth and cash management, along with promising clinical advancements. However, challenges remain with IXCHIQ sales suspension, DUKORAL sales decline, and operating losses.
Company Guidance
In the recent conference call, Valneva provided guidance on its financial performance and strategic direction for the remainder of 2025 and beyond. The company reported total revenues of EUR 127 million for the first nine months of 2025, marking an increase of nearly 9% from the previous year, despite geopolitical and product-specific challenges. Product sales reached EUR 119.4 million, with IXIARO sales growing 12.5% to EUR 74.3 million, driven by demand from the U.S. Department of Defense and European markets. However, DUKORAL sales slightly decreased to EUR 21.5 million, impacted by currency fluctuations and a distributor transition in Germany. IXCHIQ sales saw a notable increase to EUR 7.6 million, despite a temporary U.S. license suspension affecting travel segment sales. Valneva's cash reserves stood at EUR 143.5 million as of September 30, 2025, bolstered by EUR 26 million from ATM transactions. The company maintained its full-year guidance, projecting product sales between EUR 155 million and EUR 170 million, and total revenues ranging from EUR 165 million to EUR 180 million. Looking ahead, Valneva emphasized the significant potential of its Lyme disease vaccine, VLA15, which is on track for regulatory submissions in 2026 and anticipated market launch in late 2027, positioning it as a key growth driver for sustained profitability.
Revenue Growth
Total revenues reached EUR 127 million, marking a growth of almost 9% despite geopolitical and IXCHIQ-specific challenges.
Operating Cash Burn Reduction
Significant reduction in operating cash burn, resulting in a cash position of more than EUR 140 million.
Debt Refinancing Success
Successfully completed debt refinancing, enhancing financial flexibility with Pharmakon as a new partner.
IXIARO Sales Increase
IXIARO sales reached EUR 74.3 million, a 12.5% increase driven by sales to the U.S. Department of Defense and increased sales in Europe.
Positive Clinical Data
Reported positive safety and immunogenicity data for the Lyme vaccine candidate and positive Phase I results for the Zika vaccine candidate.
Valneva (VALN) Earnings, Revenues Date & History
The upcoming earnings date is based on a company’s previous reporting, and may be updated when the actual date is announced
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
VALN Earnings-Related Price Changes
Report Date
Price 1 Day Before
Price 1 Day After
Percentage Change
Nov 20, 2025
$8.70
$8.53
-1.95%
Aug 12, 2025
$8.50
$9.40
+10.59%
May 07, 2025
$6.48
$6.59
+1.70%
Mar 20, 2025
$6.73
$7.25
+7.73%
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
FAQ
When does Valneva Se (VALN) report earnings?
Valneva Se (VALN) is schdueled to report earning on Mar 19, 2026, TBA (Confirmed).
What is Valneva Se (VALN) earnings time?
Valneva Se (VALN) earnings time is at Mar 19, 2026, TBA (Confirmed).
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.